Ypsomed carves out diabetes business in $512M deal to focus on GLP-1 self-injectors
Ypsomed plans to trade its insulin pump arm to a new Swiss medtech, TecMed, in a deal worth up to 420 million francs or about $513 million.
Ypsomed plans to trade its insulin pump arm to a new Swiss medtech, TecMed, in a deal worth up to 420 million francs or about $513 million.
